U.S. FDA Approves Boehringer Ingelheim’s JASCAYD® (nerandomilast) Tablets as First New Treatment for Adults with Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim USFDA Approval Boehringer Ingelheim JASCAYD® (nerandomilast) tablets are  approved by the U.S. FDA as an oral treatment for idiopathic pulmonary fibrosis ( IPF ) in adult patients...